The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: Preliminary data

Diabetes and Vascular Disease Research

Volumn 3, Issue 3, 2006, Pages 186-188

  Coletta, Dawn K ^a,e   Bates, Sarah H ^b   Jones, Robert B ^c   Bailey, Clifford J ^d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c RenaSci Ltd   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Basal plasma glucose; Hepatic gluconeogenesis; Insulin mediated glucose uptake; Mice; Sibutramine

Indexed keywords

AMINE; DEOXYGLUCOSE; DRUG METABOLITE; INSULIN; LACTIC ACID; PYRUVIC ACID; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; LIVER METABOLISM; MUSCLE METABOLISM; NONHUMAN; SATIETY; SINGLE DRUG DOSE; SOLEUS MUSCLE; TISSUE CULTURE; WEIGHT REDUCTION;

ANIMALS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCONEOGENESIS; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MICE; MUSCLE, SKELETAL; TIME FACTORS;

EID: 33845382597     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2006.028     Document Type: Article

References (21)

1. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-84.
2. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-18.
3. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6.
4. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord 1998;22:619-23.
5. Scheen AJ, Lefebvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000;16:114-24.
6. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000;2:105-12.
7. Serrano-Rios M, Melchionda N, Moreno-Carretero E; Spanish Investigators. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002;19:119-24.
8. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22:18-28.
9. Weyer C, Hanson K, Bogardus C, Pratley RE. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. Diabetologia 2000;43:36-46.
10. Bailey CJ, Turner SL, Bates SH, Jones RB. Sibutramine metabolites increase glucose transport by cultured rat muscle cells. Int J Obes Relat Metab Disord 2001;25:478-85.
11. Bailey CJ, Bates SH, Turner SL, Rossi M, Morgan I, Bloom SR. Leptin improves insulin sensitivity of skeletal muscle in obese-diabetic ob/ob mice. Pharm Pharmacol Commun 2000;6:35-9.
12. Stevens JF. Determination of glucose by an automatic analyser. Clin Chim Acta 1971;32:199-201.
13. Pollard MR, Dutton GJ. Liver snips. A simple, rapid and reproducible method for studying metabolism in small fragments of tissue, as applied to glucuronidation in rat liver. Biochem J 1982;202:469-73.
14. Penicaud L, Kande J, Le Magnen J, Girard JR. Insulin action during fasting and refeeding in rat determined by euglycemic clamp. Am J Physiol 1985;249:514-18.
15. Issad T, Penicaud L, Ferre P, Kande J, Baudon MA, Girard J. Effects of fasting on tissue glucose utilization in conscious resting rats. Major glucose-sparing effect in working muscles. Biochem J 1987;246:241-4.
16. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-24.
17. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.
18. Day C, Bailey CJ. Sibutramine update. Brit J Diab Vasc Dis 2002;2:392-7.
19. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.
20. Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
21. Newsholme EA, Start C. Regulation in metabolism. London: Wiley, 1973: 349.